

Date: December 28,2023

To,

NSE LIMITED

EXCHANGE PLAZA, 5TH FLOOR,
PLOT NO. C/1, G BLOCK, BANDRA-KURLA COMPLEX,
BANDRA (EAST), MUMBAI 400 051.

SYMBOL: REMUS

Dear Sir/Madam,

Sub: Intimation under Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements), 2015 ("Listing Regulations")

We refer to our letter dated August 04, 2023, wherein the Board of Directors approved incorporation of subsidiary company in Bolivia. We wish to inform you that the subsidiary company in name and style of Relius Pharma S.R.L. has been incorporated. The Board of Directors in their meeting held on today i.e. December 28,2023 have approved the infusion of funds by way of subscription of authorized capital in the said subsidiary company.

Disclosures as required under Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 are enclosed herewith as Annexure – I.

You are requested to take the aforesaid information on your record.

**Thanking you
Yours Sincerely,
For, Remus Pharmaceuticals Limited**

PATEL DEVAL
BAKULKUMAR

Digitally signed by PATEL
DEVAL BAKULKUMAR
Date: 2023.12.28 19:12:46
+05'30'

Deval Patel
Company Secretary
Membership No.: A60090



Encl: a/a

Remus Pharmaceuticals Limited

REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad-380054,
Gujarat, India.
P: 079 2999 9857

E: remus@remuspharma.com | W: www.remuspharma.com

GST NO: 24AAHCR4771P2ZQ | CIN NO: L24232GJ2015PLC084536

Annexure -I

Details required under the Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015

Sr. No	Particulars	Description
1.	Name of the target company, details in brief such as size, turnover etc.;	Name: Relius Pharma S.R.L. Authorized Capital: 1,70,000 Bolivian Boliviano Turnover: Nil (Yet to Commence Business Operations)
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	Yes The company incorporated is a subsidiary company.
3.	Industry to which the entity being acquired belongs	Pharmaceuticals
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The object of incorporation of the Subsidiary is to expand business in Bolivia and other nearby countries.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable
6.	Indicative time period for completion of the acquisition	The Company has been incorporated.
7.	Nature of consideration – whether cash consideration or share swap and details of the same	Cash Consideration towards subscription of Authorized Capital.
8.	Cost of acquisition or the price at which the shares are acquired	The Company would infuse up to USD 25,000 equivalent to 1,68,300 Bolivian Boliviano in Share Capital in one or more tranches.
9.	Percentage of shareholding/control acquired and/or number of shares acquired	99%
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Brief background: The main business activity of the Company is wholesale trade of medicine pharmaceutical products. Line of business: Pharmaceuticals Date of Incorporation: 13/10/2023 History of last 3 years turnover: This is a newly incorporated Company and therefore history of last 3 years turnover is not available.

Remus Pharmaceuticals Limited

REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.

P: 079 2999 9857

E. remus@remuspharma.com | W. www.remuspharma.com

GST NO: 24AAHCR4771P2ZQ | CIN NO: L24232GJ2015PLC084536